London, 08 February, Haffingtonpost: It is one of the highly rated matter that breast cancer drug that can increase survival rates for pancreatic cancer is being made available in the UK for private patients. Nab-paclitaxel, marketed as Abraxane, has shown improvements when given to patients with advanced pancreatic cancer in combination with standard chemotherapy.
Average survival increased from 6.7 months to 8.5 months. One year survival rates rose from 22% to 35% and at two years they doubled from 4% to 9%, according to a study published in the New England Journal of Medicine last year.
Pancreatic cancer is one of the deadliest cancers, killing 80% of the 8,500 people diagnosed every year in the UK within 12 months. It claimed the life of Hollywood star Patrick Swayze and featured in Coronation Street when character Hayley Cropper developed the disease. Abraxane, which costs around £600 a month, has now been made available to patients in the UK through private clinics. Manufacturer Celgene has applied for the drug to be added to the NHS Cancer Drugs Fund list. An application is also being submitted to the National Institute for Health and Clinical Excellence (Nice), which appraises drugs for use on the NHS.